Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3333
Structure:
Synonyms:
(+)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
(+-)-Ethyl methyl
(+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
(+/-) ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
1A Brand of Felodipine
3,5-Pyridinedicarboxylic acid 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester (- );
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (+-)-
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-,ethyl methyl ester, (+-)-
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester
72509-76-3
86189-69-7
AbZ Brand of Felodipine
AE-641/11429675
Agon
AGON SR
Aliud Brand of Felodipine
Alphapharm Brand of Felodipine
Alpharma Brand of Felodipine
Ambap1004
Astra Brand of Felodipine
AstraZeneca Brand of Felodipine
Aventis Brand of Felodipine
Azupharma Brand of Felodipine
BC Brand of Felodipine
betapharm Brand of Felodipine
BPBio1_000678
BRN 4331472
BSPBio_000616
C18H19Cl2NO4
CGH-869
CHEBI:585948
ct Arzneimittel Brand of Felodipine
ct-Arzneimittel Brand of Felodipine
D00319
D015736
DB01023
dl-Felodipine
ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
EU-0100508
F9677_SIGMA
Felo Biochemie
Felo Puren
Felo-Puren
Felobeta
Felocor
Feloday
Felodipin 1A Pharma
Felodipin AbZ
Felodipin AL
Felodipin AZU
Felodipin dura
Felodipin Heumann
Felodipin ratiopharm
Felodipin Stada
felodipin von ct
Felodipin-ratiopharm
Felodipina
Felodipina [INN-Spanish]
FELODIPINE
Felodipine (JAN/USP/INN)
Felodipine [INN:BAN]
Felodipine [USAN:BAN:INN]
Felodipine [USAN:INN:BAN]
Felodipinum
Felodipinum [INN-Latin]
Felodur
Felodur ER
Felogamma
Felogard
Fensel
Flodil
H 154 82
H 154-82
H 154/82
H 15482
H-154/82
Heumann Brand of Felodipine
Heumann, Felodipin
Hexal Brand of Felodipine
Hoechst Brand of Felodipine
Hydac
Lexxel
Logimax
Lopac0_000508
LS-131202
Merck dura Brand of Felodipine
Mixture Name
MLS000069629
MLS001077361
MLS001333735
MLS002153409
MLS002153832
Modip
Munobal
Munobal Retard
NCGC00093906-01
NCGC00093906-02
O3-ethyl O5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Penedil
Perfudal
Pharmaceutica Astra Brand of Felodipine
Pharmacia Spain Brand of Felodipine
Plendil
Plendil (TN)
Plendil Depottab
Plendil ER
Plendil Retard
Preslow
Prestwick0_000478
Prestwick1_000478
Prestwick2_000478
Prestwick3_000478
Prestwick_797
Prevex
Promed Brand of Felodipine
ratiopharm Brand of Felodipine
Renedil
SMR000058204
SPBio_002555
Splendil
Stadapharm Brand of Felodipine
TheraPharm Brand of Felodipine
W?rwag Brand of Felodipine
ATC-Codes:
Side-Effects:
Side-EffectFrequency
insomnia0.0010
tachycardia0.0010
syncope0.0010
sexual dysfunction0.0010
pruritis0.0010
polyuria0.0010
nervousness0.0010
myocardial infarction0.0010
muscle cramps0.0010
flu0.0010
tremor0.0010
urticaria0.0010
urinary frequency0.0010
bradycardia0.0010
photosensitivity0.0010
regurgitation0.0010
myalgia0.0010
leucocytoclastic vasculitis0.0010
urinary urgency0.0010
dry mouth0.0010
vomiting0.0010
impotence0.0010
postural hypotension0.0010
hypotension0.0010
confusion0.0010
chest pain0.0010
arthralgia0.0010
arrhythmia0.0010
anxiety0.0010
angioedema0.0010
angina pectoris0.0010
anemia0.0010
abdominal pain0.0010
diarrhea0.0010
somnolence0.0010
dyspnea0.0010
salivary gland enlargement0.0010
hepatitis0.0010
flatulence0.0010
fever0.0010
erythema nodosum0.0010
erythema multiforme0.0010
epistaxis0.0010
edema0.0010
dysuria0.0010
arm pain0
palpitations0
sneezing0
sinusitis0
peripheral edema0
bronchitis0
hip pain0
decreased libido0
nausea0
infection0
flushing0
headache0
irritability0
asthenia0
dyspepsia0
rhinorrhea0
rash0
foot pain0
back pain0
constipation0
paresthesia0
cough0
knee pain0
leg pain0
upper respiratory tract infection0
dizziness0
pharyngitis0
gynecomastia0
erythema0

Target

show target details
Uniprot ID:CP2C9_HUMAN
Synonyms:
(R)-limonene 6-monooxygenase
(S)-limonene 6-monooxygenase
(S)-limonene 7-monooxygenase
CYPIIC9
Cytochrome P450 2C9
P-450MP
P450 MP-4/MP-8
P450 PB-1
S-mephenytoin 4-hydroxylase
EC-Numbers:1.14.13.48
1.14.13.49
1.14.13.80
Organism:Homo sapiens
Human
PDB IDs:1OG2 1OG5 1R9O
Structure:
1R9O

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

10640508
Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.. B Ma; T Prueksaritanont; J H Lin (2000) Drug metabolism and disposition: the biological fate of chemicals display abstract
The inhibitory effects of six commonly used calcium channel blockers on three major cytochrome P-450 activities were examined and characterized in human liver microsomes. All six compounds reversibly inhibited CYP2D6 (bufuralol 1'-hydroxylation) and CYP2C9 (tolbutamide methyl hydroxylation) activities. The IC(50) values for the inhibition of CYP2D6 and CYP2C9 for nicardipine were 3 to 9 microM, whereas those for all others ranged from 14 to >150 microM. Except for nifedipine, all calcium channel blockers showed increased inhibitory potency toward CYP3A activities (testosterone 6beta-hydroxylation and midazolam 1'-hydroxylation) after 30-min preincubation with NADPH. IC(50) values for the inhibition of testosterone 6beta-hydroxylase obtained in the NADPH-preincubation experiment for nicardipine (1 microM), verapamil (2 microM), and diltiazem (5 microM) were within 10-fold, whereas those for amlodipine (5 microM) and felodipine (13 microM) were >200-fold of their respective plasma concentrations reported after therapeutic doses. Similar results also were obtained based on midazolam 1'-hydroxylase activity. Unlike the observations with mibefradil, a potent irreversible inhibitor of CYP3A, the NADPH-dependent inhibition of CYP3A activity by nicardipine and verapamil was completely reversible on dialysis, whereas that by diltiazem was partially restored (80%). Additional experiments revealed that nicardipine, verapamil, and diltiazem formed cytochrome P-450-iron (II)-metabolite complex in both human liver microsomes and recombinant CYP3A4. Nicardipine yielded a higher extent of complex formation ( approximately 30% at 100 microM), and was a much faster-acting inhibitor (maximal inhibition rate constant approximately 2 min(-1)) as compared with verapamil and diltiazem. These present findings that the CYP3A inhibition caused by nicardipine, verapamil, and diltiazem is, at least in part, quasi-irreversible provide a rational basis for pharmacokinetically significant interactions reported when they were coadministered with agents that are cleared primarily by CYP3A-mediated pathways.